<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Sources – Mallinckrodt / Endo / Keenova / Par Health</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta
    name="description"
    content="Linked public sources used to build the Mallinckrodt / Endo / Keenova / Par Health timeline and litigation overview."
  />
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet" />
  <link rel="stylesheet" href="style.css" />
</head>
<body>
<header>
  <div class="nav-inner">
    <div class="brand">
      <div class="brand-logo"></div>
      <div>
        <div class="brand-text-main">Keenova / Par Health</div>
        <div class="brand-text-sub">Source Documents &amp; Articles</div>
      </div>
    </div>
    <button class="nav-toggle" aria-label="Toggle navigation">
      <span></span>
      <span></span>
    </button>
    <nav class="nav-links">
      <a href="index.html">Overview</a>
      <a href="timeline.html">Timeline</a>
      <a href="litigation.html">Litigation</a>
      <a href="sources.html" class="nav-cta">Sources</a>
    </nav>
  </div>
</header>

<main class="page-shell">
  <section class="section">
    <div class="section-header">
      <div>
        <div class="section-kicker">Public Record</div>
        <h2 class="section-title">Selected sources for this site</h2>
      </div>
      <p class="section-subtitle">
        This is the backbone. If a fact cannot be tied to at least one of these sources, it is intentionally not included.
      </p>
    </div>

    <div class="card">
      <div class="card-header">
        <h3 class="card-title">Core filings, trust sites and AG summaries</h3>
        <p class="card-subtitle">Bankruptcy-related and settlement-related materials</p>
      </div>
      <div class="card-body">
        <ul class="sources-list">
          <li>
            <a href="https://www.opioidmasterdisbursementtrust.com/Mallinckrodt" target="_blank" rel="noopener noreferrer">
              Mallinckrodt Opioid Master Disbursement Trust II (MDT&nbsp;II) – official site
            </a>
            <span>Describes MDT&nbsp;II’s role as a “hub” trust, funding schedule and creditor trust structure for Mallinckrodt’s opioid settlements.</span>
          </li>
          <li>
            <a href="https://oag.ca.gov/opioids" target="_blank" rel="noopener noreferrer">
              California Attorney General – National Opioids Settlements &amp; opioid bankruptcies
            </a>
            <span>Summarizes Mallinckrodt’s and Endo’s opioid settlement obligations and trust arrangements from a state AG perspective.</span>
          </li>
          <li>
            <a href="https://ncdoj.gov/attorney-general-josh-stein-announces-updated-settlement-with-opioid-manufacturer-mallinckrodt/" target="_blank" rel="noopener noreferrer">
              North Carolina Attorney General – Mallinckrodt settlement details
            </a>
            <span>Details the structured payment framework and trust funding amounts for Mallinckrodt’s opioid resolution.</span>
          </li>
          <li>
            <a href="https://endotrust.com/" target="_blank" rel="noopener noreferrer">
              Endo Public Opioid Trust – official site
            </a>
            <span>Explains the Endo Public Opioid Trust’s beneficiaries, distribution schedule and governance.</span>
          </li>
          <li>
            <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/mallinckrodt-gets-approval-restructuring-1-billion-cut-opioid-settlement-2023-10-10/" target="_blank" rel="noopener noreferrer">
              Reuters – “Court OKs Mallinckrodt restructuring, $1 billion cut to opioid settlement” (Oct&nbsp;10&nbsp;2023)
            </a>
            <span>Describes court approval of Mallinckrodt’s second bankruptcy plan, including reduced opioid obligations and cancelled equity.</span>
          </li>
          <li>
            <a href="https://www.davispolk.com/experience/mallinckrodt-emerges-chapter-11" target="_blank" rel="noopener noreferrer">
              Davis Polk – “Mallinckrodt emerges from chapter 11” (Nov&nbsp;16&nbsp;2023)
            </a>
            <span>Summarizes the restructuring terms, take-back debt and new capital structure for Mallinckrodt.</span>
          </li>
          <li>
            <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-endo-receives-us-court-approval-bankruptcy-restructuring-2024-03-19/" target="_blank" rel="noopener noreferrer">
              Reuters – “Drugmaker Endo receives US court approval for bankruptcy restructuring” (Mar&nbsp;19&nbsp;2024)
            </a>
            <span>Reports on Endo’s plan confirmation, lender ownership and funding for the Endo Public Opioid Trust and other settlements.</span>
          </li>
          <li>
            <a href="https://www.justice.gov/archives/opa/pr/opioid-manufacturer-endo-health-solutions-inc-ordered-pay-1536b-criminal-fines-and" target="_blank" rel="noopener noreferrer">
              U.S. Department of Justice – Endo Health Solutions opioid misbranding case (May&nbsp;3&nbsp;2024)
            </a>
            <span>Details the criminal fines and forfeiture related to misbranded Opana&nbsp;ER and how they relate to Endo’s bankruptcy resolution.</span>
          </li>
          <li>
            <a href="https://www.biopharmadive.com/news/mallinckrodt-bankruptcy-chapter-11-opioids/586836/" target="_blank" rel="noopener noreferrer">
              BioPharma Dive – “Mallinckrodt, beset by opioid drug suits, files for bankruptcy” (Oct&nbsp;12&nbsp;2020)
            </a>
            <span>Provides context on how opioid lawsuits and Acthar-related disputes contributed to Mallinckrodt’s first Chapter&nbsp;11 filing.</span>
          </li>
          <li>
            <a href="https://www.ag.ky.gov/pdf_news/20171106_Complaint.pdf" target="_blank" rel="noopener noreferrer">
              Kentucky Attorney General – Opioid complaint against Endo
            </a>
            <span>Alleges deceptive marketing of Opana and Opana&nbsp;ER, outlining the state’s theory of Endo’s role in the opioid crisis.</span>
          </li>
        </ul>
      </div>
    </div>

    <div class="card" style="margin-top:16px;">
      <div class="card-header">
        <h3 class="card-title">Merger, spin-off and business-press coverage</h3>
        <p class="card-subtitle">News sources used for deal mechanics and narrative</p>
      </div>
      <div class="card-body">
        <ul class="sources-list">
          <li>
            <a href="https://www.ft.com/content/86ad051e-94d3-4003-8f99-737dd7662400" target="_blank" rel="noopener noreferrer">
              Financial Times – “Mallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisis”
            </a>
            <span>Frames the merger as a post-bankruptcy combination, with details on valuation, revenue, ownership split and opioid settlements.</span>
          </li>
          <li>
            <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-mallinckrodt-endo-merge-nearly-7-billion-deal-2025-03-13/" target="_blank" rel="noopener noreferrer">
              Reuters – “Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal” (Mar&nbsp;13&nbsp;2025)
            </a>
            <span>Reports on the announcement, enterprise value, expected revenue and NYSE listing plans.</span>
          </li>
          <li>
            <a href="https://www.marketwatch.com/story/mallinckrodt-and-endo-to-combine-in-6-7-billion-stock-and-cash-deal-0b9084f9" target="_blank" rel="noopener noreferrer">
              MarketWatch – Mallinckrodt &amp; Endo to combine in $6.7&nbsp;billion deal
            </a>
            <span>Provides additional context on transaction structure and strategic rationale.</span>
          </li>
          <li>
            <a href="https://www.investopedia.com/drugmakers-mallinckrodt-endo-to-merge-plan-nyse-listing-11696081" target="_blank" rel="noopener noreferrer">
              Investopedia – “Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing”
            </a>
            <span>Explains expected listing, enterprise value and pro forma portfolio mix.</span>
          </li>
          <li>
            <a href="https://www.mallinckrodt.com/" target="_blank" rel="noopener noreferrer">
              Mallinckrodt.com – corporate site (Keenova &amp; Par Health information)
            </a>
            <span>States the July&nbsp;31&nbsp;2025 merger date and November&nbsp;2025 spin-off and rebrand to Keenova and Par Health.</span>
          </li>
          <li>
            <a href="https://pharmaphorum.com/news/irelands-mallinckrodt-closes-spinout-rebrands-keenova" target="_blank" rel="noopener noreferrer">
              Pharmaphorum – “Ireland’s Mallinckrodt closes spinout, rebrands as Keenova” (Nov&nbsp;2025)
            </a>
            <span>Provides sales, headcount and strategic positioning for Keenova and Par Health.</span>
          </li>
          <li>
            <a href="https://www.biospace.com/press-releases/par-health-completes-spin-off-from-mallinckrodt-creating-an-independent-leader-in-generic-pharmaceuticals-and-sterile-injectables" target="_blank" rel="noopener noreferrer">
              BioSpace / PR Newswire – “Par Health completes spin-off from Mallinckrodt…”
            </a>
            <span>Describes Par Health’s focus on generics, APIs and sterile injectables and its manufacturing footprint.</span>
          </li>
          <li>
            <a href="https://www.fiercepharma.com/pharma/merger-books-mallinckrodt-and-endo-rebrand-keenova-spin-generics-business-par-health" target="_blank" rel="noopener noreferrer">
              FiercePharma – coverage of Keenova rebrand &amp; Par Health spin-off
            </a>
            <span>Frames the combined group’s repositioning after opioid-related pressure and restructurings.</span>
          </li>
        </ul>
      </div>
    </div>
  </section>

  <section class="section" id="disclosure">
    <div class="disclosure">
      <p>
        <strong>Prepared by:</strong> Ted Nawrocki. This site is an independent synthesis of publicly available information from
        the sources listed above. It is for educational and informational purposes only and does not provide investment, legal,
        tax, accounting or medical advice, nor any recommendation regarding any security, issuer or transaction.
      </p>
    </div>

    <footer>
      <div>© 2025 Ted Nawrocki. All rights reserved.</div>
      <div>All trademarks and company names are the property of their respective owners.</div>
    </footer>
  </section>
</main>

<script src="script.js"></script>
</body>
</html>

